Fasiplon
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
6-Ethyl-7-methoxy-5-methyl-2-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyrimidine
|
|
| Identifiers | |
| CAS Number | 106100-65-6  |
| ATC code | none |
| PubChem | CID 208954 |
| ChemSpider | 181047  |
| UNII | XCA050IPGB |
| ChEMBL | CHEMBL62735 |
| Chemical data | |
| Formula | C13H15N5O2 |
| Molar mass | 273.290 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Fasiplon (RU 33203) is a nonbenzodiazepine anxiolytic drug from the imidazopyrimidine family of drugs.
Fasiplon binds strongly to benzodiazepine sites on the GABAA receptor and has similar anxiolytic effects in animals, but with less sedative or muscle relaxant action.[1] It was developed by a team at Roussel Uclaf in the 1990s[2]
References[edit]
- ^ Tully WR, Gardner CR, Gillespie RJ, Westwood R (July 1991). "2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors". Journal of Medicinal Chemistry. 34 (7): 2060–7. doi:10.1021/jm00111a021. PMID 1648620.
- ^ US Patent 5869481 Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
